Myriad Genetics 8-K
PositiveDeal pending
Deal to sell prenatal testing to Labcorp for $210M cash plus inventory aims to strengthen the balance sheet.
Filed 2026-10-20 08:36 ET
- 1.01 Entry into a Material Agreement
- 7.01 Regulation FD Disclosure
- 9.01 Financial Statements and Exhibits
Summary
Myriad agreed to sell its prenatal health testing business to Labcorp for $210M in cash plus the business’s inventory value at closing. The sale covers Foresight, Prequel and FirstGene prenatal screens and SneakPeek; Labcorp will offer comparable terms to certain business employees. The deal is subject to regulatory clearance and customary closing conditions and is expected to close by early 2027. Myriad expects the transaction to support revenue growth and profitability and strengthen its balance sheet.
Key Figures
- Either party may terminate if the deal has not closed by 2/19/2027; the deadline automatically extends to 10/19/2027 if regulatory clearances remain outstanding but all other closing conditions are satisfied or waived. In certain regulatory-clearance termination circumstances, Labcorp would owe Myriad a $10.5M termination fee.
- A patent license agreement takes effect at closing; the parties also expect to enter into a transition services agreement and other ancillary agreements.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Labcorp revenue addition | Year one | ≈$160M | — | — |
| Labcorp adjusted earnings (non-GAAP) | Year one | Slightly accretive | — | — |
| Labcorp Diagnostics segment margins | By end of year two, once fully integrated | Reach average segment margins | — | — |
Investor Takeaways
- Regulatory clearance and the expected early-2027 closing are the next milestones.
- Myriad plans to discuss the transaction and related organizational changes on its 11/04/2026 third-quarter earnings call.
The summary is written by an AI model reading the filing.
Model 005 · prompt v95 · 2026-10-20 14:35:03Z